ECDC
East Coast Diversified Corp.
stock OTC

For naysayers, check out my DD on Gopro and where it ended after it was published here.
\*\*TLDR:\*\*
INO ($1.37, \~$110M market cap) is surging on a confirmed \*\*Andes hantavirus outbreak\*\* aboard the MV Hondius cruise ship (multiple cases, 3 deaths, possible person-to-person spread). Inovio has the only clinical-stage DNA vaccine experience against relevant hantavirus strains (Hantaan, Puumala, Andes) via prior DoD/NIAID-backed programs. In a panic/funding scenario, this micro-cap DNA platform play could realistically hit \*\*$50+\*\* (30-40x) as the purest speculative vaccine stock — classic biotech moonshot with massive upside but high risk of fading if the outbreak fizzles.
\---
\*\*INO Due Diligence: The Hantavirus Outbreak Catalyst – Why $50+ Is Realistic in a Panic Scenario (May 2026)\*\*
\*\*Current Snapshot (as of May 8, 2026)\*\*
\- \*\*Price\*\*: \~$1.35–$1.37
\- \*\*Market Cap\*\*: \~$110M (roughly 81M shares outstanding)
\- \*\*Status\*\*: Micro-cap DNA medicine biotech with a clean but quiet balance sheet (cash runway into late 2026 post-recent offering). Lead asset INO-3107 (RRP) has BLA under FDA review with PDUFA October 30, 2026 — but that’s not why the stock is moving today.
The real driver right now: \*\*A confirmed hantavirus cluster on the MV Hondius cruise ship\*\* (Atlantic, originated near South America). As of early May 2026: multiple cases, 3 deaths, international passengers involved. Suspected \*\*Andes virus strain\*\* (the only hantavirus with documented limited human-to-human transmission). WHO, ECDC, and national health agencies are actively responding. Panic is building — exactly the setup that sends speculative vaccine plays parabolic.
\*\*Why INO Is the Purest Hantavirus Play on the Board\*\*
Inovio isn’t starting from zero on hantavirus. They have \*\*actual clinical-stage data\*\* — the only public company that does:
\- \*\*Phase 1 hantavirus DNA vaccine trials\*\* (Hantaan/HTNV and Puumala/PUUV strains) using their CELLECTRA electroporation delivery system. Data showed the vaccines were safe and generated immune responses in humans.
\- \*\*2011 U.S. Department of Defense SBIR grant\*\* specifically for a multi-vaccine DNA delivery device tested on \*\*Hantaan virus\*\* (a key hantavirus) and Lassa.
\- Earlier NIAID- and U.S. Army-backed studies on Andes virus DNA vaccine candidates to prevent hantavirus pulmonary syndrome (HPS).
Inovio’s DNA platform + CELLECTRA was literally used in these programs. They have the patents, the know-how, the prior human safety/immunogenicity data, and a track record of rapid sequence-to-vaccine design.
\*\*Hantavirus 101 – Why This Outbreak Matters\*\*
\- Rodent-borne normally, but Andes strain (South American) has shown \*\*person-to-person transmission\*\*.
\- Hantavirus Pulmonary Syndrome (HPS) has \~38% fatality rate. No approved vaccine or specific treatment exists.
\- A cruise ship cluster with international passengers = instant global exposure and fear. If it spreads or new clusters appear, governments will throw money at rapid-response countermeasures. Exactly like 2020.
\*\*The Bull Case – Path to $50+ (37x from here)\*\*

For naysayers, check out my DD on Gopro and where it ended after it was published here.
\*\*TLDR:\*\*
INO ($1.37, \~$110M market cap) is surging on a confirmed \*\*Andes hantavirus outbreak\*\* aboard the MV Hondius cruise ship (multiple cases, 3 deaths, possible person-to-person spread). Inovio has the only clinical-stage DNA vaccine experience against relevant hantavirus strains (Hantaan, Puumala, Andes) via prior DoD/NIAID-backed programs. In a panic/funding scenario, this micro-cap DNA platform play could realistically hit \*\*$50+\*\* (30-40x) as the purest speculative vaccine stock — classic biotech moonshot with massive upside but high risk of fading if the outbreak fizzles.
\---
\*\*INO Due Diligence: The Hantavirus Outbreak Catalyst – Why $50+ Is Realistic in a Panic Scenario (May 2026)\*\*
\*\*Current Snapshot (as of May 8, 2026)\*\*
\- \*\*Price\*\*: \~$1.35–$1.37
\- \*\*Market Cap\*\*: \~$110M (roughly 81M shares outstanding)
\- \*\*Status\*\*: Micro-cap DNA medicine biotech with a clean but quiet balance sheet (cash runway into late 2026 post-recent offering). Lead asset INO-3107 (RRP) has BLA under FDA review with PDUFA October 30, 2026 — but that’s not why the stock is moving today.
The real driver right now: \*\*A confirmed hantavirus cluster on the MV Hondius cruise ship\*\* (Atlantic, originated near South America). As of early May 2026: multiple cases, 3 deaths, international passengers involved. Suspected \*\*Andes virus strain\*\* (the only hantavirus with documented limited human-to-human transmission). WHO, ECDC, and national health agencies are actively responding. Panic is building — exactly the setup that sends speculative vaccine plays parabolic.
\*\*Why INO Is the Purest Hantavirus Play on the Board\*\*
Inovio isn’t starting from zero on hantavirus. They have \*\*actual clinical-stage data\*\* — the only public company that does:
\- \*\*Phase 1 hantavirus DNA vaccine trials\*\* (Hantaan/HTNV and Puumala/PUUV strains) using their CELLECTRA electroporation delivery system. Data showed the vaccines were safe and generated immune responses in humans.
\- \*\*2011 U.S. Department of Defense SBIR grant\*\* specifically for a multi-vaccine DNA delivery device tested on \*\*Hantaan virus\*\* (a key hantavirus) and Lassa.
\- Earlier NIAID- and U.S. Army-backed studies on Andes virus DNA vaccine candidates to prevent hantavirus pulmonary syndrome (HPS).
Inovio’s DNA platform + CELLECTRA was literally used in these programs. They have the patents, the know-how, the prior human safety/immunogenicity data, and a track record of rapid sequence-to-vaccine design.
\*\*Hantavirus 101 – Why This Outbreak Matters\*\*
\- Rodent-borne normally, but Andes strain (South American) has shown \*\*person-to-person transmission\*\*.
\- Hantavirus Pulmonary Syndrome (HPS) has \~38% fatality rate. No approved vaccine or specific treatment exists.
\- A cruise ship cluster with international passengers = instant global exposure and fear. If it spreads or new clusters appear, governments will throw money at rapid-response countermeasures. Exactly like 2020.
\*\*The Bull Case – Path to $50+ (37x from here)\*\*